<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Empiric antimicrobial agent selection for acute complicated urinary tract infection</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Empiric antimicrobial agent selection for acute complicated urinary tract infection</h1>
<div class="graphic"><div class="figure"><div class="ttl">Empiric antimicrobial agent selection for acute complicated urinary tract infection</div><div class="cntnt"><table cellspacing="0"><colgroup span="2" width="20%"></colgroup><colgroup span="2" width="30%"></colgroup> <tbody> <tr class="divider_bottom"> <td class="subtitle1">Patient population</td> <td class="subtitle1">Risk for MDR?<sup>*</sup></td> <td class="subtitle1">Empiric regimens</td> <td class="subtitle1">Comments</td> </tr> <tr class="divider_bottom"> <td>Hospitalized with: <ul class="decimal_heading"> <li>Critical illness warranting intensive care (eg, severe sepsis) <strong>or</strong></li> <li>Urinary tract obstruction</li> </ul> </td> <td>N/A</td> <td> In regions where community prevalence of ESBL-producing organisms is high or uncertain: <ul class="decimal_heading"> <li>An antipseudomonal carbapenem: <ul> <li>Imipenem 500 mg IV every 6 hours infused over 3 hours <strong>or</strong></li> <li>Meropenem 1 g IV every 8 hours infused over 3 hours</li> </ul> </li> <li class="none"><strong>plus</strong></li> <li>Vancomycin 15 to 20 mg/kg IV every 8 to 12 hours with or without a loading dose</li> </ul> <hr/> In regions where community prevalence of ESBL-producing organisms is low: <ul class="decimal_heading"> <li>Select a regimen based on individual MDR risk, as listed for "Other hospitalized patients"</li> </ul> </td> <td> <ul> <li>The rationale for broad coverage is the high risk of adverse outcomes with insufficient antimicrobial therapy.</li> <li>When broad-spectrum regimens are used empirically, it is important to tailor the regimen if culture and susceptibility testing indicate that a narrower agent would be active.</li> </ul> </td> </tr> <tr> <td class="divider_bottom" rowspan="2">Other hospitalized patients</td> <td>No</td> <td> <ul> <li>Ceftriaxone 1 g IV once daily</li> <li>Alternatives: <ul> <li>Levofloxacin 750 mg IV or orally daily</li> <li>Ciprofloxacin 400 mg IV twice daily</li> <li>Ciprofloxacin 500 mg orally twice daily</li> <li>Ciprofloxacin extended-release 1000 mg orally once daily</li> </ul> </li> </ul> </td> <td> Concern for particular pathogens (eg, because of prior isolates) should further inform antibiotic selection: <ul class="decimal_heading"> <li>If <em>Enterococcus</em> is suspected (eg, based on prior isolates), piperacillin-tazobactam is active against this and gram-negatve pathogens.</li> <li>If drug-resistant gram-positive organisms are suspected, vancomycin (for MRSA) or linezolid or daptomycin (for VRE) should be added to the gram-negative agent (eg, ceftriaxone).</li> <li>If <em>Pseudomonas</em> is suspected, piperacillin-tazobactam, cefepime, or a fluoroquinolone are appropriate options.</li> </ul> </td> </tr> <tr class="divider_bottom"> <td>Yes</td> <td> <ul> <li>Piperacillin-tazobactam 3.375 g IV every 6 hours <strong>or</strong></li> <li>Cefepime 2 g IV every 12 hours (not for ESBL risk) <strong>or</strong></li> <li>An antipseudomonal carbapenem (if recent ESBL isolate): <ul> <li>Imipenem 500 mg IV every 6 hours infused over 3 hours <strong>or</strong></li> <li>Meropenem 1 g IV every 8 hours infused over 3 hours</li> </ul> </li> </ul> </td> <td> <ul> <li>If VRE or MRSA are suspected (eg, based on prior isolates), vancomycin (for MRSA) or daptomycin or linezolid (for VRE) is added.</li> </ul> </td> </tr> <tr> <td rowspan="3">Outpatients</td> <td>No, and no concerns with fluoroquinolones (eg, at low risk for adverse effects)</td> <td>For patients with low risk of fluoroquinolone resistance/toxicity: <ul class="decimal_heading"> <li>Ciprofloxacin 500 mg orally twice daily for 5 to 7 days <strong>or</strong></li> <li>Ciprofloxacin extended-release 1000 mg orally once daily for 5 to 7 days <strong>or</strong></li> <li>Levofloxacin 750 mg orally once daily for 5 to 7 days</li> </ul> </td> <td> <ul> <li>If the community prevalence of fluoroquinolone resistance in <em>Escherichia</em> coli is known to be &gt;10%, give one dose of a long-acting parenteral agent prior to the fluoroquinolone: <ul> <li>Ceftriaxone 1 g IV or IM once</li> <li>Ertapenem 1 g IV or IM once</li> <li>Gentamicin 5 mg/kg IV or IM once</li> <li>Tobramycin 5 mg/kg IV or IM once</li> </ul> </li> </ul> </td> </tr> <tr> <td>No, but with concerns with fluoroquinolones (eg, at risk for adverse effects)</td> <td>For patients who cannot use a fluoroquinolone: <ul class="decimal_heading"> <li>One dose of a long-acting parenteral agent: <ul> <li>Ceftriaxone 1 g IV or IM once <strong>or</strong></li> <li>Ertapenem 1 g IV or IM once <strong>or</strong></li> <li>Gentamicin 5 mg/kg IV or IM once <strong>or</strong></li> <li>Tobramycin 5 mg/kg IV or IM once</li> </ul> </li> <li>Followed by one of the following: <ul> <li>TMP-SMX one double-strength tablet orally twice daily for 7 to 10 days <strong>or</strong></li> <li>Amoxicillin-clavulanate 875 mg orally twice daily for 7 to 10 days <strong>or</strong></li> <li>Cefpodoxime 200 mg orally twice daily for 7 to 10 days <strong>or</strong></li> <li>Cefadroxil 1 g orally twice daily for 7 to 10 days</li> </ul> </li> </ul> </td> <td> <ul> <li>In outpatients who are systemically ill or are at risk for more severe illness, we favor continuing the parenteral agent until culture and susceptibility testing results can guide selection of an appropriate oral agent.</li> </ul> </td> </tr> <tr> <td>Yes</td> <td> <ul> <li>Ertapenem 1g IV or IM once</li> <li>Followed by: <ul> <li>Ciprofloxacin 500 mg orally twice daily for 5 to 7 days <strong>or</strong></li> <li>Ciprofloxacin extended-release 1000 mg orally once daily for 5 to 7 days <strong>or</strong></li> <li>Levofloxacin 750 mg orally daily for 5 to 7 days</li> </ul> </li> </ul> </td> <td> <ul> <li>If the patient cannot take a fluoroquinolone or has high risk for fluoroquinolone resistance (fluoroquinolone-resistant isolate or fluoroquinolone use in prior three months): <ul> <li>Ertapenem 1 g IV or IM once daily until cultures and susceptibility testing return</li> </ul> </li> </ul> </td> </tr> </tbody></table></div><div class="graphic_lgnd">These antibiotic regimens represent our approach to empiric treatment for acute complicated UTI. Once culture and susceptibility testing results are available, the regimen should be tailored to those results. If feasible, an antibiotic with a narrow spectrum of activity should be chosen to complete the antibiotic course.</div><div class="graphic_footnotes"><p>IM: intramuscular; 
        IV: intravenous; 
        MDR: multidrug resistance;  
        MRSA: methicillin-resistant <em>Staphylococcus aureus</em>; 
        TMP-SMX: trimethoprim-sulfamethoxazole; 
        UTI: urinary tract infection;
        VRE: vancomycin-resistant <em>Enterococcus</em>.</p>
    
    * Risk factors for MDR gram-negative UTIs include any one of the following in the prior three months:
    <ul>
<li>An MDR, gram-negative urinary isolate, including a fluoroquinolone-resistant <em>Pseudomonas</em> urinary isolate</li>
<li>Inpatient stay at a health care facility (eg, hospital, nursing home, long-term acute care facility)</li>
<li>Use of a fluoroquinolone, TMP-SMX, or broad-spectrum beta-lactam (eg, third- or later-generation cephalosporin)</li>
<li>Travel to parts of the world with high rates of MDR organisms</li>
</ul></div><div id="graphicVersion">Graphic 131022 Version 4.0</div></div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
